Analysts’ Opinions Are Mixed on These Healthcare Stocks: HealthStream (HSTM), Legend Biotech (LEGN) and Immuneering (IMRX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on HealthStream (HSTM – Research Report), Legend Biotech (LEGN – Research Report) and Immuneering (IMRX – Research Report).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
HealthStream (HSTM)
In a report released today, Vincent Colicchio from Barrington maintained a Hold rating on HealthStream. The company’s shares closed last Wednesday at $24.56, close to its 52-week low of $23.92.
According to TipRanks.com, Colicchio is a 5-star analyst with an average return of
The the analyst consensus on HealthStream is currently a Moderate Buy rating.
See the top stocks recommended by analysts >>
Legend Biotech (LEGN)
In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on Legend Biotech, with a price target of $70.00. The company’s shares closed last Wednesday at $31.18, close to its 52-week low of $30.17.
According to TipRanks.com, Goonewardene ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $69.38, which is an 112.7% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $74.00 price target.
Immuneering (IMRX)
In a report released today, Geulah Livshits from Chardan Capital maintained a Buy rating on Immuneering, with a price target of $20.00. The company’s shares closed last Wednesday at $6.62.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
Immuneering has an analyst consensus of Strong Buy, with a price target consensus of $16.67, a 144.1% upside from current levels. In a report issued on October 31, Leerink Partners also initiated coverage with a Buy rating on the stock with a $15.00 price target.
Read More on HSTM:
